Clinical Trial Update: Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating orelabrutinib in combination with romiplostim for primary immune thrombocytopenia; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Romiplostim (romiplostim)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 2 | Status: NOT_YET_RECRUITING